You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
|
|---|---|
| Published in |
British Journal of Cancer, June 2015
|
| DOI | 10.1038/bjc.2015.196 |
| Pubmed ID | |
| Authors |
M E Gore, C Szczylik, C Porta, S Bracarda, G A Bjarnason, S Oudard, S-H Lee, J Haanen, D Castellano, E Vrdoljak, P Schöffski, P Mainwaring, R E Hawkins, L Crinò, T M Kim, G Carteni, W E E Eberhardt, K Zhang, K Fly, E Matczak, M J Lechuga, S Hariharan, R Bukowski |
| Abstract |
We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials. Patients ⩾18 years received oral sunitinib 50 mg per day on a 4-weeks-on-2-weeks-off schedule. Safety was assessed regularly. Tumour measurements were scheduled per local practice. A total of 4543 patients received sunitinib. Median treatment duration and follow-up were 7.5 and 13.6 months. Objective response rate was 16% (95% confidence interval (CI): 15-17). Median progression-free survival (PFS) and overall survival (OS) were 9.4 months (95% CI: 8.8-10.0) and 18.7 months (95% CI: 17.5-19.5). Median PFS in subgroups of interest: aged ⩾65 years (33%), 10.1 months; Eastern Cooperative Oncology Group performance status ⩾2 (14%), 3.5 months; non-clear cell histology (12%), 6.0 months; and brain metastases (7%), 5.3 months. OS was strongly associated with the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model (n=4065). The most common grade 3/4 treatment-related adverse events were thrombocytopenia (10%), fatigue (9%), and asthenia, neutropenia, and hand-foot syndrome (each 7%). Final analysis of the sunitinib expanded-access trial provided a good opportunity to evaluate the long-term side effects of a tyrosine kinase inhibitor used worldwide in mRCC. Efficacy and safety findings were consistent with previous results.British Journal of Cancer advance online publication, 18 June 2015; doi:10.1038/bjc.2015.196 www.bjcancer.com. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 14% |
| United States | 1 | 14% |
| Unknown | 5 | 71% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 71% |
| Practitioners (doctors, other healthcare professionals) | 2 | 29% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 1% |
| Unknown | 90 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 19% |
| Other | 9 | 10% |
| Student > Ph. D. Student | 9 | 10% |
| Student > Bachelor | 8 | 9% |
| Student > Master | 8 | 9% |
| Other | 16 | 18% |
| Unknown | 24 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 45% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Agricultural and Biological Sciences | 5 | 5% |
| Nursing and Health Professions | 2 | 2% |
| Other | 3 | 3% |
| Unknown | 28 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#1,616,199
of 24,356,663 outputs
Outputs from British Journal of Cancer
#706
of 10,791 outputs
Outputs of similar age
#20,314
of 268,603 outputs
Outputs of similar age from British Journal of Cancer
#15
of 124 outputs
Altmetric has tracked 24,356,663 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,791 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 10.0. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,603 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 124 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.